Juno Therapeutics, Inc. (NASDAQ:JUNO) was the target of unusually large options trading activity on Tuesday. Traders acquired 6,838 put options on the company. This represents an increase of 977% compared to the typical volume of 635 put options.

A number of equities analysts have weighed in on JUNO shares. Vetr upgraded shares of Juno Therapeutics to a “buy” rating in a research report on Tuesday, May 23rd. Wedbush reiterated a “neutral” rating and issued a $24.00 price target on shares of Juno Therapeutics in a research report on Friday, May 5th. BidaskClub upgraded shares of Juno Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, June 27th. Morgan Stanley dropped their price target on shares of Juno Therapeutics from $27.00 to $26.00 and set an “equal weight” rating for the company in a research report on Monday, May 8th. Finally, FBR & Co reiterated a “hold” rating on shares of Juno Therapeutics in a research report on Thursday, May 18th. Three analysts have rated the stock with a sell rating, six have assigned a hold rating and eight have issued a buy rating to the company’s stock. Juno Therapeutics has an average rating of “Hold” and a consensus target price of $31.86.

In other Juno Therapeutics news, EVP Robert Azelby sold 12,869 shares of the company’s stock in a transaction that occurred on Tuesday, August 29th. The shares were sold at an average price of $39.95, for a total value of $514,116.55. Following the completion of the transaction, the executive vice president now directly owns 50,289 shares in the company, valued at $2,009,045.55. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, major shareholder Douglas K. Bratton sold 8,000,000 shares of the company’s stock in a transaction that occurred on Thursday, July 13th. The stock was sold at an average price of $27.00, for a total transaction of $216,000,000.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 8,066,369 shares of company stock valued at $218,108,557. Company insiders own 15.26% of the company’s stock.

Large investors have recently added to or reduced their stakes in the stock. Broadfin Capital LLC boosted its stake in Juno Therapeutics by 49.2% in the second quarter. Broadfin Capital LLC now owns 262,100 shares of the biopharmaceutical company’s stock worth $7,834,000 after buying an additional 86,400 shares in the last quarter. Wasatch Advisors Inc. bought a new stake in Juno Therapeutics during the second quarter worth about $19,787,000. Public Employees Retirement System of Ohio boosted its stake in Juno Therapeutics by 115.3% in the second quarter. Public Employees Retirement System of Ohio now owns 56,326 shares of the biopharmaceutical company’s stock worth $1,684,000 after buying an additional 30,170 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in Juno Therapeutics by 809,500.0% in the second quarter. Tower Research Capital LLC TRC now owns 16,192 shares of the biopharmaceutical company’s stock worth $484,000 after buying an additional 16,190 shares in the last quarter. Finally, The Manufacturers Life Insurance Company boosted its stake in Juno Therapeutics by 7.2% in the second quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock worth $102,000 after buying an additional 228 shares in the last quarter. 70.76% of the stock is currently owned by hedge funds and other institutional investors.

Juno Therapeutics (NASDAQ:JUNO) opened at 41.27 on Friday. The company’s 50 day moving average is $29.97 and its 200-day moving average is $25.69. The company’s market cap is $4.33 billion. Juno Therapeutics has a 12 month low of $17.52 and a 12 month high of $43.10.

Juno Therapeutics (NASDAQ:JUNO) last released its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.72) by $0.24. Juno Therapeutics had a negative net margin of 354.36% and a negative return on equity of 27.10%. The company had revenue of $21.30 million during the quarter, compared to analyst estimates of $15.59 million. During the same period in the prior year, the business posted ($0.64) EPS. Juno Therapeutics’s revenue was down 22.8% compared to the same quarter last year. On average, analysts expect that Juno Therapeutics will post ($3.12) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/09/01/juno-therapeutics-sees-unusually-high-options-volume-juno.html.

Juno Therapeutics Company Profile

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Receive News & Stock Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related stocks with our FREE daily email newsletter.